Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vaccinex, Inc. Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024 July 17, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease June 06, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports 2023 Financial Results and Provides Corporate Update April 02, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules March 27, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology February 21, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex, Inc. Announces Reverse Stock Split February 15, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces Pricing of $3.7 Million PIPE Financing February 07, 2024 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule December 04, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting October 31, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases October 26, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces Pricing of $9.6 Million Public Offering September 28, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration September 28, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application September 27, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer September 26, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex, Inc. Announces Reverse Stock Split September 22, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET June 01, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update May 15, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab April 25, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells April 12, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces Private Placement with Commitments of $5.0 Million April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference March 23, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) March 21, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis March 09, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology January 09, 2023 From Vaccinex, Inc. Via GlobeNewswire Tickers SURF VCNX Vaccinex Announces $3.8 Million Private Placement November 28, 2022 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update November 14, 2022 From Vaccinex, Inc. Via GlobeNewswire Tickers VCNX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.